Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation

Gut

Volumn 63, Issue 8, 2014, Pages 1300-1312

  Esposito, Giuseppe ^a   Capoccia, Elena ^a   Turco, Fabio ^b   Palumbo, Ilaria ^b   Lu, Jie ^c   Steardo, Antonio ^a   Cuomo, Rosario ^b   Sarnelli, Giovanni ^b   Steardo, Luca ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; NITRIC OXIDE; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROSTAGLANDIN E2; PROTEIN S100B; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DISEASE ACTIVITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENTERIC GLIAL CELL; FEMALE; GLIA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MACROPHAGE MIGRATION; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLENOMEGALY; ULCERATIVE COLITIS;

ENTERIC NERVOUS SYSTEM; GUT INFLAMMATION; NERVOUS CONTROL OF INTESTINAL FUNCTIONS; ULCERATIVE COLITIS;

ANILIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; COLITIS; COLITIS, ULCERATIVE; COLON, SIGMOID; CYCLOOXYGENASE 2; DEXTRAN SULFATE; DINOPROSTONE; ENDOCANNABINOIDS; ETHANOLAMINES; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INDOLES; MALE; MICE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROGLIA; NEUTROPHIL INFILTRATION; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PALMITIC ACIDS; PPAR ALPHA; PPAR GAMMA; RECTUM; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893911893     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305005     Document Type: Article

References (45)

1. Monteleone G, Pallone F, MacDonald TT. Emerging immunological targets in inflammatory bowel disease. Curr Opin Pharmacol 2011;11:640-5.
2. Helper DJ, Rex DK. Inflammatory bowel disease. Endoscopy 2001;33:140-6. (Pubitemid 32586378)
3. Rühl A, Nasser Y, Sharkey KA. Enteric glia. Neurogastroenterol Motil 2004;16:44-9. (Pubitemid 38580940)
4. Ben-Horin S, Chowers Y. Neuroimmunology of the gut: physiology, pathology, and pharmacology. Curr Opin Pharmacol 2008;8:490-5.
5. Abdo H, Derkinderen P, Gomes P, et al. Enteric glial cells protect neurons from oxidative stress in part via reduced glutathione. FASEB 2009;24:1-3.
6. Savidge TC, Newman P, Pothoulakis C, et al. Enteric glia regulate intestinal barrier function and inflammation via release of S- nitrosoglutathione. Gastroenterology 2007;132:1344-58. (Pubitemid 46656255)
7. Esposito G, Cirillo C, Sarnelli G, et al. Enteric glial-derived S100B protein stimulates nitric oxide production in celiac disease. Gastroenterology 2007;133:918-25. (Pubitemid 47374127)
8. Cornet A, Savidge TC, Cabarrocas J, et al. Enterocolitis induced by autoimmune targeting of enteric glial cells: A possible mechanism in Crohn's disease? Proc Natl Acad Sci USA 2001;98:13306-11. (Pubitemid 33051358)
9. Burns AJ, Pachnis V. Development of the enteric nervous system: bringing together cells, signals and genes. Neurogastroenterol Motil 2009;21:100-2.
10. Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132:26-37. (Pubitemid 46108761)
11. Von Boyen GB, Steinkamp M, Geerling I, et al. Proinflammatory cytokines induce neurotrophic factor expression in enteric glia: A key to the regulation of epithelial apoptosis in Crohn's disease. Inflamm Bowel Dis 2006;12:346-54.
12. Cirillo C, Sarnelli G, Esposito G, et al. Increased mucosal nitric oxide production in ulcerative colitis is mediated in part by the enteroglial-derived S100B protein. Neurogastroenterol Motil 2009;21:1209-112.
13. Cirillo C, Sarnelli G, Esposito G, et al. S100B protein in the gut: The evidence for enteroglial-sustained intestinal inflammation. World J Gastroenterol 2011;17:1261-6.
14. Cirillo C, Sarnelli G, Turco F, et al. Proinflammatory stimuli activates human-derived enteroglial cells and induces autocrine nitric oxide production. Neurogastroenterol Motil 2011;23:372-82.
15. Turco F, Sarnelli G, Cirillo C, et al. Enteroglial-derived S100B protein integrates bacteria-induced Toll-like receptor signalling in human enteric glial cells. Gut 2014;63:105-15.
16. Petrosino S, Iuvone T, Di Marzo V. N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie 2010;92:724-7.
17. Luongo L, Guida F, Boccella S, et al. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol Disord Drug Targets 2013;12:45-54.
18. Genovese T, Esposito E, Mazzon E, et al. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther 2008;326:12-23. (Pubitemid 351872139)
19. D'Agostino G, La Rana G, Russo R, et al. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-κB nuclear signalling in dorsal root ganglia. Eur J Pharmacol 2009;613:54-9.
20. Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator- Activated receptor- Alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005;67:15-9. (Pubitemid 40069962)
21. Costa B, Conti S, Giagnoni G, et al. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol 2002;137:413-20. (Pubitemid 35221894)
22. Ross RA, Brockie HC, Pertwee RG. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur J Pharmacol 2000;401:121-30. (Pubitemid 30488186)
23. Farquhar-Smith WP, Jaggar SI, Rice AS. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain 2002;97:11-21. (Pubitemid 34603305)
24. Endocannabinoid Research Group; De Filippis D, D'Amico A, Cipriano M, et al. Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacol Res 2010;61:321-8.
25. Capasso R, Izzo AA, Fezza F, et al. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol 2001;134:945-50. (Pubitemid 33052152)
26. Costa B, Comelli F, Bettoni I, et al. Pain The endogenous fatty acid amide, palmitoylethanolamide, has anti- Allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. 2008;139:541-50.
27. Brown WH, Gillum MP, Lee HY, et al. Fatty acid amide hydrolase ablation promotes ectopic lipid storage and insulin resistance due to centrally mediated hypothyroidism. Proc Natl Acad Sci USA 2012;109:14966-71.
28. Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-49.
29. Di Rosa M, Radomski M, Carnuccio R, et al. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun 1990;172:1246-52.
30. Thoree V, Skepper J, Deere H, et al. Phenotype of exogenous microparticle-containing pigment cells of the human Peyer's patch in inflamed and normal ileum. Inflamm Res 2008;57:374-8.
31. Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 1985;14:157-67. (Pubitemid 15241170)
32. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta- Analysis. Am J Gastroenterol 2011;106:590-9.
33. Lichtenstein GR, Gordon GL, Zakko S, et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis- A 6-month placebo-controlled trial. Aliment Pharmacol Ther 2010;32:990-9.
34. Cottone M, Renna S, Orlando A, et al. Medical management of Crohn's disease. Expert Opin Pharmacother 2011;12:2505-25.
35. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136:1182-97.
36. Fok KC, Ng WW, Henderson CJ, et al. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J Crohns Colitis 2012;6:708-12.
37. Veerappan SG, Kennedy M, O'Morain CA, et al. Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis. Eur J Gastroenterol Hepatol 2008;20:588-9. (Pubitemid 351667903)
38. Scheinfeld N. Adalimumab: A review of side effects. Expert Opin Drug Saf 2005;4:637-41. (Pubitemid 40946062)
39. Cabarrocas J, Savidge TC, Liblau RS. Role of enteric glial cells in inflammatory bowel disease. Glia 2003;41:81-93. (Pubitemid 36164287)
40. Esposito G, De Filippis D, Cirillo C, et al. The astroglial-derived S100B protein stimulates the expression of nitric oxide synthase in rodent macrophages through p38 MAP kinase activation. Life Sci 2006;78:2707-15.
41. Barajon I, Serrao G, Arnaboldi F, et al. Toll-like receptors 3, 4, and 7 are expressed in the enteric nervous system and dorsal root ganglia. J Histochem Cytochem 2009;57:1013-23.
42. Ji Y, Wang Z, Li Z, et al. Modulation of LPS-mediated inflammation by fenofibrate via the TRIF-dependent TLR4 signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem 2010;25:631-40.
43. De Filippis D, Negro L, Vaia M, et al. New insights in mast cell modulation by palmitoylethanolamide. CNS Neurol Disord Drug Targets 2013;12:78-83.
44. Darmani NA, Izzo AA, Degenhardt B, et al. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 2005;48:1154-63. (Pubitemid 40725988)
45. Cravatt BF, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty- Acid amides. Nature 1996;384:83-7. (Pubitemid 26374593)